A Reversal for Loncar Cancer Immunotherapy ETF (CNCR) Is Not Near. The Formed Head & Shoulders Chart Pattern

July 14, 2018 - By Harriett Tippett

The stock of Loncar Cancer Immunotherapy ETF (CNCR) formed H&S with $24.29 target or 3.00 % below today’s $25.04 share price. The 8 months Head & Shoulders indicates high risk for the $57.83 million company. It was reported on Jul, 14 by Faxor.com. If the $24.29 price target is reached, the company will be worth $1.73 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The ETF decreased 0.40% or $0.1 during the last trading session, reaching $25.04. About 25,881 shares traded. Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) has risen 25.36% since July 14, 2017 and is uptrending. It has outperformed by 12.79% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: